CN Patent

CN119585250A — Kit抑制剂

Assigned to Blueprint Medicines Corp · Expires 2025-03-07 · 1y expired

What this patent protects

本公开的一个实施方案是一种由式(I)表示的化合物或其药学上可接受的盐。式(I)中的变量在本文中定义。 式(I)化合物可用于抑制突变型KIT蛋白和治疗人或非人的与异常KIT活性相关的疾患。

USPTO Abstract

本公开的一个实施方案是一种由式(I)表示的化合物或其药学上可接受的盐。式(I)中的变量在本文中定义。 式(I)化合物可用于抑制突变型KIT蛋白和治疗人或非人的与异常KIT活性相关的疾患。

Drugs covered by this patent

Patent Metadata

Patent number
CN119585250A
Jurisdiction
CN
Classification
—
Expires
2025-03-07
Drug substance claim
No
Drug product claim
No
Assignee
Blueprint Medicines Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.